Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “market perform” rating reaffirmed by Wells Fargo & Company in a report released on Thursday.

Several other brokerages have also weighed in on TEVA. Vetr raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating and set a $32.27 target price on the stock in a research report on Wednesday, June 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $37.00 target price (down from $38.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, July 17th. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $21.00 target price (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, August 31st. Finally, BTIG Research raised Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Monday, September 11th. Five analysts have rated the stock with a sell rating, eighteen have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $29.39.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 2.49% on Thursday, reaching $15.68. The company had a trading volume of 37,585,420 shares. The firm’s market capitalization is $15.93 billion. The company’s 50-day moving average price is $16.99 and its 200 day moving average price is $26.97. Teva Pharmaceutical Industries Limited has a 52 week low of $15.22 and a 52 week high of $45.85. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading on Wednesday. Stock investors acquired 29,656 put options on the stock. This is an increase of 231% compared to the typical daily volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period last year, the business posted $1.25 earnings per share. On average, analysts expect that Teva Pharmaceutical Industries Limited will post $4.28 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Given “Market Perform” Rating at Wells Fargo & Company” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/05/teva-pharmaceutical-industries-limited-teva-given-market-perform-rating-at-wells-fargo-company.html.

A number of large investors have recently bought and sold shares of the stock. Capital Research Global Investors grew its stake in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. grew its stake in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares in the last quarter. FMR LLC grew its stake in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares in the last quarter. Northern Cross LLC grew its stake in Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after purchasing an additional 2,184,172 shares in the last quarter. Finally, Nordea Investment Management AB grew its stake in Teva Pharmaceutical Industries Limited by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock worth $428,033,000 after purchasing an additional 311,894 shares in the last quarter. Institutional investors and hedge funds own 56.77% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.